Effector Therapeutics Inc (EFTR) - Total Assets
Based on the latest financial reports, Effector Therapeutics Inc (EFTR) holds total assets worth $27.13 Million USD as of March 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Effector Therapeutics Inc - Total Assets Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Effector Therapeutics Inc (EFTR) total market value for the company's overall valuation and market capitalisation.
Effector Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Effector Therapeutics Inc's total assets of $27.13 Million consist of 96.6% current assets and 3.4% non-current assets. Review Effector Therapeutics Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.4% |
| Accounts Receivable | $52.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Effector Therapeutics Inc (EFTR) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Effector Therapeutics Inc's current assets represent 96.6% of total assets in 2023, an increase from 83.9% in 2019.
- Cash Position: Cash and equivalents constituted 72.4% of total assets in 2023, up from 67.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Effector Therapeutics Inc Competitors by Total Assets
Key competitors of Effector Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Effector Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 0.78 | 1.89 |
| Quick Ratio | 1.03 | 0.79 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $681.00K | $-5.76 Million | $7.80 Million |
Effector Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Effector Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | $20.54 Million |
| Market Capitalization | $940.00 USD |
Valuation Analysis
Below Book Valuation: The market values Effector Therapeutics Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Effector Therapeutics Inc's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Effector Therapeutics Inc (2019–2023)
The table below shows the annual total assets of Effector Therapeutics Inc from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $20.54 Million | -29.35% |
| 2022-12-31 | $29.08 Million | -46.21% |
| 2021-12-31 | $54.06 Million | +223.61% |
| 2020-12-31 | $16.70 Million | +227.85% |
| 2019-12-31 | $5.09 Million | -- |
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more